Compare TRDA & JILL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRDA | JILL |
|---|---|---|
| Founded | 2016 | 1959 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Clothing/Shoe/Accessory Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.6M | 246.5M |
| IPO Year | 2021 | 2017 |
| Metric | TRDA | JILL |
|---|---|---|
| Price | $6.95 | $19.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $21.00 | $17.00 |
| AVG Volume (30 Days) | ★ 299.4K | 51.3K |
| Earning Date | 05-08-2026 | 06-10-2026 |
| Dividend Yield | N/A | ★ 2.42% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.31 |
| Revenue | $25,421,000.00 | ★ $596,549,000.00 |
| Revenue This Year | $39.97 | $2.65 |
| Revenue Next Year | $50.80 | N/A |
| P/E Ratio | ★ N/A | $63.97 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.02 | $10.41 |
| 52 Week High | $16.45 | $20.89 |
| Indicator | TRDA | JILL |
|---|---|---|
| Relative Strength Index (RSI) | 49.66 | 60.83 |
| Support Level | $5.71 | $15.40 |
| Resistance Level | $7.95 | N/A |
| Average True Range (ATR) | 0.41 | 0.80 |
| MACD | -0.03 | -0.09 |
| Stochastic Oscillator | 37.37 | 56.58 |
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
J.Jill Inc is a national lifestyle brand that provides apparel, footwear, and accessories. The company's products are marketed under the J.Jill brand name and sold through its two channels: its e-commerce platform and catalog (Direct) and its retail stores (Retail). J.Jill caters to a distinctive set of women, typically forty-five years and older, offering them various apparel products, footwear, and accessories, comprising shirts, dresses, tops and tees, sweaters, pants and jeans, jewelry, bags, belts, shoes, scarves, etc. The company's operating segments consist of its Retail channels, which derive maximum revenue, and Direct channels. Geographically, the majority of its revenue is derived from the United States.